Arena Pharmaceuticals, Inc. (ARNA) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Price: $99.98 --0%
Financial Fact:
Net loss per share allocable to common stockholders, basic: -0.05
Today's EPS Names:
PKE, BYRN, HELE, More
Financial Fact:
Net loss per share allocable to common stockholders, basic: -0.05
Today's EPS Names:
PKE, BYRN, HELE, More
Join SI Premium – FREE
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) reported Q1 EPS of ($0.12), $0.02 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $6.8 million versus the consensus estimate of $7.98 million.
For earnings history and earnings-related data on Arena Pharmaceuticals, Inc. (ARNA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Humana soars, Alignment Healthcare sinks on Medicare rating changes
- Oil-Dri Corp. (ODC) Reports Q4 EPS of $1.00
- PepsiCo shares climb after Q3 beat, though company trims profit forecast
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
